A Novartis Pharmaceuticals official advocated sharing biomarker data among industry in a US Food and Drug Administration webcast discussing the agency’s “Critical Path” initiative.

Providing that pharma can protect its intellectual property, it would be advantageous for industry to pool biomarker data, Mathias Hukkelhoven, senior vice president and global head of drug regulatory affairs of Basel, Switzerland-based Novartis, said.